Generic Name and Formulations:
Norethindrone 0.35mg (28 tabs).
Indications for JOLIVETTE:
Continuous regimen: 1 tab daily.
Breast carcinoma. Undiagnosed abnormal genital bleeding. Liver tumors. Acute liver disease. Pregnancy (Cat.X).
Cigarette smoking. Do physical exams at least annually. Discontinue if migraine or other serious headaches occur. Use back-up contraception for 48 hours if taken 3 hours or more late. Nursing mothers: if not exclusively breastfeeding may start 3 weeks after delivery; if fully breastfeeding may start 6 weeks after delivery.
Antagonized by hepatic enzyme-inducing drugs (eg, phenobarbital, rifampin).
Menstrual irregularities, frequent or irregular bleeding, mastodynia, headache, nausea, dizziness; androgenic effects (rare).
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Endocrine Society Released Guidelines for Managing Endocrine Disorders in Childhood Cancer Survivors
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|